MX2021011810A - Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as. - Google Patents

Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.

Info

Publication number
MX2021011810A
MX2021011810A MX2021011810A MX2021011810A MX2021011810A MX 2021011810 A MX2021011810 A MX 2021011810A MX 2021011810 A MX2021011810 A MX 2021011810A MX 2021011810 A MX2021011810 A MX 2021011810A MX 2021011810 A MX2021011810 A MX 2021011810A
Authority
MX
Mexico
Prior art keywords
treatment
lung cancer
small cell
cell lung
egfr
Prior art date
Application number
MX2021011810A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Francis Patrick Nash
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2021011810A publication Critical patent/MX2021011810A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021011810A 2019-03-29 2020-03-27 Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as. MX2021011810A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825867P 2019-03-29 2019-03-29
PCT/EP2020/058729 WO2020201097A1 (en) 2019-03-29 2020-03-27 Osimertinib for use in the treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
MX2021011810A true MX2021011810A (es) 2021-10-26

Family

ID=70224330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011810A MX2021011810A (es) 2019-03-29 2020-03-27 Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.

Country Status (11)

Country Link
US (1) US12465608B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946346A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022526159A (cg-RX-API-DMAC7.html)
KR (2) KR102992349B1 (cg-RX-API-DMAC7.html)
CN (1) CN113645976A (cg-RX-API-DMAC7.html)
AU (2) AU2020250832A1 (cg-RX-API-DMAC7.html)
CA (1) CA3133766A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192552A1 (cg-RX-API-DMAC7.html)
MA (1) MA55508A (cg-RX-API-DMAC7.html)
MX (1) MX2021011810A (cg-RX-API-DMAC7.html)
WO (1) WO2020201097A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259147A4 (en) * 2020-12-11 2024-10-23 Erasca, Inc. Combination therapies for the treatment of cancer
CN117098537A (zh) * 2020-12-11 2023-11-21 医睿世康药业研发公司 用于癌症治疗的联合疗法
US20240309363A1 (en) * 2021-01-12 2024-09-19 Georgia Tech Research Corporation Combination therapeutics for treatment of proliferative disorders
CN119768173A (zh) * 2022-09-01 2025-04-04 齐鲁制药有限公司 一种egfr激酶抑制剂的用途
TW202515577A (zh) * 2023-06-27 2025-04-16 日商大鵬藥品工業股份有限公司 患有具有egfr畸變的非小細胞肺癌之個體的治療方法
CN121177212B (zh) * 2025-11-25 2026-03-03 中南大学湘雅二医院 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
WO2006068826A2 (en) 2004-12-21 2006-06-29 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
JP5249770B2 (ja) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
WO2007067506A2 (en) 2005-12-05 2007-06-14 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
EP2040546A4 (en) 2006-06-22 2009-12-23 Merck & Co Inc tyrosine kinase inhibitor
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
CA2663599A1 (en) * 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2012501654A (ja) 2008-09-05 2012-01-26 アビラ セラピューティクス, インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
CN102713618B (zh) 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
CA2778265A1 (en) 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
ES2622138T3 (es) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
DK3686193T3 (da) 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
AU2014324478A1 (en) * 2013-09-30 2016-05-05 Amgen, Inc. Nucleic acid biomarker and use thereof
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN107530434A (zh) * 2015-04-23 2018-01-02 免疫医疗有限公司 非小细胞肺癌egfr突变阳性的联合疗法
WO2017200016A1 (ja) 2016-05-17 2017-11-23 公益財団法人がん研究会 Egfr-tki耐性を獲得した肺癌の治療薬
WO2018102827A1 (en) 2016-12-04 2018-06-07 Expression Pathology, Inc. Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
MA51823A (fr) 2018-02-12 2021-05-19 Astrazeneca Ab Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER

Also Published As

Publication number Publication date
EP3946346A1 (en) 2022-02-09
AU2023233122B2 (en) 2025-07-24
CN113645976A (zh) 2021-11-12
JP2022526159A (ja) 2022-05-23
KR102992349B1 (ko) 2026-07-15
US12465608B2 (en) 2025-11-11
CA3133766A1 (en) 2020-10-08
US20220175783A1 (en) 2022-06-09
KR20260115768A (ko) 2026-07-24
AU2023233122A1 (en) 2023-10-05
JP2025131642A (ja) 2025-09-09
EA202192552A1 (ru) 2021-12-17
WO2020201097A1 (en) 2020-10-08
KR20210144844A (ko) 2021-11-30
MA55508A (fr) 2022-02-09
AU2020250832A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
EA202192552A1 (ru) Осимертиниб для применения в лечении немелкоклеточного рака легкого
Gelatti et al. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Klempner et al. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first-or second-generation EGFR TKI
MX2022014903A (es) Tki de egfr para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
Socinski et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines
Shaw et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC)(PROFILE 1007)
Kuwano et al. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
BR112023025903A2 (pt) Composto para uso no tratamento de carcinoma de células escamosas, composto para uso no tratamento de câncer de cabeça e pescoço, métodos para tratar carcinoma de células escamosas e para tratar câncer de cabeça e pescoço e usos de um composto
MX2009007987A (es) Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
RU2013148814A (ru) Биомаркеры для прогнозирования чувствительности к противоопухолевой терапии
EP4378530A3 (en) Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody
MX2024011959A (es) Inhibidores de la tirosina cinasa del receptor del factor de crecimiento epidérmico (egfr) junto con un inhibidor de la akt para el tratamiento del cáncer.
Jiao et al. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation
MX2022008874A (es) Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
Shea et al. Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation–positive lung adenocarcinoma
Lv et al. Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)
Gomez-Randulfe et al. Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations
EP4097140A4 (en) USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS TO TREAT CANCERS WITH NRG1 GENE FUSIONS
Singh et al. Clinical experience on use of oral EGFR-TKIs as first-line treatment of advanced NSCLC from a tertiary care centre in North India and implications of skin rash
Liang-an Comparison of therapeutic effects between EGFR-TKI in first-line and second-line therapy in non-small cell lung cancer (NSCLC) patients
HK40126841A (en) Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
IL318241A (en) Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF receptor inhibitors for cancer treatment
Chen Clinical application of epidermal growth factor receptor-tyrosine kinase inhibitors against non-small cell lung cancer
Salari et al. 38. Who's driving treatment? Two co-occurring driver mutations in Primary Lung Adenocarcinoma
Gulyaeva et al. Signaling cascades are targets for breast cancer therapy in the light of genome–wide sequencing data